Conexiant’s news site is now MDSpire News. Learn more
Advertisement
Short-Term Use of Selective COX-2 Inhibitors for Musculoskeletal Pain Management in Patients with Remission of Inflammatory Bowel Disease: A Narrative Review
Clinical Scorecard: Short-Term Use of Selective COX-2 Inhibitors for Musculoskeletal Pain Management in Patients with Remission of Inflammatory Bowel Disease: A Narrative Review
At a Glance
Category
Detail
Condition
Inflammatory Bowel Disease (IBD)
Key Mechanisms
Selective COX-2 inhibitors reduce upper GI ulceration by preferentially inhibiting COX-2 while sparing COX-1.
Target Population
Patients with IBD in remission experiencing musculoskeletal pain.
Care Setting
Clinical management of musculoskeletal symptoms in patients with IBD.
Key Highlights
Short-term selective COX-2 inhibitors may be used for musculoskeletal pain in IBD patients in remission.
Two placebo-controlled trials showed no higher rates of IBD relapse vs placebo during short-term treatment.
Open-label studies reported variable GI adverse events and symptom worsening.
Treatment should be time-limited and use the lowest effective dose.
Routine safety assessment is required due to potential cardiovascular risks.
Guideline-Based Recommendations
Diagnosis
Evaluate musculoskeletal symptoms in patients with IBD.
Management
Consider short-term use of selective COX-2 inhibitors for pain management in IBD patients in remission.
Monitoring & Follow-up
Include clinical monitoring for gastrointestinal and cardiovascular safety.
Risks
Monitor for potential gastrointestinal injury and cardiovascular risks associated with COX-2 inhibitors.
Patient & Prescribing Data
Patients with inflammatory bowel disease in remission.
Cautious use of selective COX-2 inhibitors is supported for managing musculoskeletal pain.
Clinical Best Practices
Limit the duration of COX-2 inhibitor therapy.
Use the lowest effective dose for pain management.
Conduct routine safety assessments during treatment.
Large claims analysis finds no significant differences in serious infections, blood clots, or major cardiovascular events across biologics and a Janus kinase inhibitor.
